CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Fundamental Analysis

NASDAQ:CMMB • US16385C2035

1.86 USD
+0.31 (+20%)
At close: Feb 27, 2026
1.83 USD
-0.03 (-1.61%)
Pre-Market: 3/2/2026, 8:57:15 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

CMMB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. While CMMB has a great health rating, there are worries on its profitability. CMMB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CMMB has reported negative net income.
  • In the past year CMMB has reported a negative cash flow from operations.
  • In the past 5 years CMMB always reported negative net income.
  • CMMB had a negative operating cash flow in each of the past 5 years.
CMMB Yearly Net Income VS EBIT VS OCF VS FCFCMMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a Return On Assets value of -106.24%, CMMB is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
  • CMMB has a Return On Equity (-121.90%) which is in line with its industry peers.
Industry RankSector Rank
ROA -106.24%
ROE -121.9%
ROIC N/A
ROA(3y)-85.25%
ROA(5y)-73.64%
ROE(3y)-107.28%
ROE(5y)-89.93%
ROIC(3y)N/A
ROIC(5y)N/A
CMMB Yearly ROA, ROE, ROICCMMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CMMB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMMB Yearly Profit, Operating, Gross MarginsCMMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The number of shares outstanding for CMMB has been increased compared to 1 year ago.
  • CMMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMMB Yearly Shares OutstandingCMMB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 1M 2M 3M
CMMB Yearly Total Debt VS Total AssetsCMMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • CMMB has an Altman-Z score of -1.64. This is a bad value and indicates that CMMB is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -1.64, CMMB is in line with its industry, outperforming 52.12% of the companies in the same industry.
  • CMMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.64
ROIC/WACCN/A
WACCN/A
CMMB Yearly LT Debt VS Equity VS FCFCMMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • CMMB has a Current Ratio of 7.42. This indicates that CMMB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 7.42, CMMB is in the better half of the industry, outperforming 71.54% of the companies in the same industry.
  • CMMB has a Quick Ratio of 7.42. This indicates that CMMB is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CMMB (7.42) is better than 71.54% of its industry peers.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.42
CMMB Yearly Current Assets VS Current LiabilitesCMMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 61.42% over the past year.
EPS 1Y (TTM)61.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CMMB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.01% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.46%
EPS Next 2Y15.53%
EPS Next 3Y4.2%
EPS Next 5Y14.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMMB Yearly Revenue VS EstimatesCMMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
CMMB Yearly EPS VS EstimatesCMMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CMMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CMMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMMB Price Earnings VS Forward Price EarningsCMMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMMB Per share dataCMMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.53%
EPS Next 3Y4.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CMMB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CHEMOMAB THERAPEUTICS LTD

NASDAQ:CMMB (2/27/2026, 8:00:00 PM)

Premarket: 1.83 -0.03 (-1.61%)

1.86

+0.31 (+20%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17
Earnings (Next)03-02
Inst Owners6.34%
Inst Owner Change-5.88%
Ins Owners9.55%
Ins Owner Change0%
Market Cap35.07M
Revenue(TTM)N/A
Net Income(TTM)-11.82M
Analysts85
Price Target17.85 (859.68%)
Short Float %2.07%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.96%
PT rev (3m)-33.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-856.25%
EPS NY rev (3m)-856.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.62
P/tB 3.62
EV/EBITDA N/A
EPS(TTM)-2.76
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS0.51
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -106.24%
ROE -121.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.25%
ROA(5y)-73.64%
ROE(3y)-107.28%
ROE(5y)-89.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.42
Altman-Z -1.64
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)40.38%
Cap/Depr(5y)224.23%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.25%
EPS Next Y43.46%
EPS Next 2Y15.53%
EPS Next 3Y4.2%
EPS Next 5Y14.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.06%
OCF growth 3YN/A
OCF growth 5YN/A

CHEMOMAB THERAPEUTICS LTD / CMMB FAQ

Can you provide the ChartMill fundamental rating for CHEMOMAB THERAPEUTICS LTD?

ChartMill assigns a fundamental rating of 2 / 10 to CMMB.


What is the valuation status for CMMB stock?

ChartMill assigns a valuation rating of 0 / 10 to CHEMOMAB THERAPEUTICS LTD (CMMB). This can be considered as Overvalued.


What is the profitability of CMMB stock?

CHEMOMAB THERAPEUTICS LTD (CMMB) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CHEMOMAB THERAPEUTICS LTD?

The Earnings per Share (EPS) of CHEMOMAB THERAPEUTICS LTD (CMMB) is expected to grow by 43.46% in the next year.